Key Finding:
The rate of reversion mutations following PARP inhibitor or platinum-based therapy is low among BRCA1/2 mutated tumors (1.0- 2.5%), possibly due to the lack of profiling post-treatment. Repeating tumor profiling at times of treatment resistance can help inform therapy selection in the refractory disease setting.